Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients

Respiratory Medicine

Volumn 104, Issue 2, 2010, Pages 228-236

  Ichinose, M ^a   Fujimoto, T ^b   Fukuchi, Y ^c  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bronchodilators; COPD; Inhalation devices; Pharmacokinetics; Tiotropium

Indexed keywords

PROPELLANT; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; ESOPHAGUS CARCINOMA; FEMALE; FORCED EXPIRATORY VOLUME; HEMORRHOID; HUMAN; INHALER; JAPANESE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PNEUMOTHORAX; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SMOKING; AGED; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; METABOLISM; METERED DOSE INHALER; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 73749084119     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.011     Document Type: Article

References (23)

1. Tashkin D., and Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 123 (2003) 1441-1449
2. Niewoehner D.E., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
3. Barr R.G., Bourbeau J., Camargo C.A., and Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 61 (2006) 854-862
4. Tashkin D.P., Celli B., Senn S., et al. for UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
5. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., and Cornelissen P.J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 55 (2000) 289-294
6. Donohue J.F., van Noord J.A., Bateman E.D., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 (2002) 47-55
7. Vincken W., van Noord J.A., Greefhorst A.P., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
8. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
9. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
10. Dusser D., Bravo M.L., and Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27 (2006) 547-555
11. Celli B., ZuWallack R., Wang S., and Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124 (2003) 1743-1748
12. O'Donnell D.E., Flüge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
13. Casaburi R., Kukafka D., Cooper C.B., Witek Jr. T.J., and Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127 (2005) 809-817
14. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1 Suppl. 12 (1999) S19-S24
15. ® Soft Mist Inhaler™ and pressurized metered dose inhalers. J Aerosol Med 18 (2005) 273-282
16. Newman S.P. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 12 Suppl. 1 (1999) S25-S31
17. ® dry powder inhaler. J Aerosol Med 18 (2005) 264-272
18. Caillaud D., Le Merre C., Martinat Y., Aguilaniu B., and Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2 (2007) 559-565
19. van Noord J.A., Cornelissen P.J.G., Aumann J.-L., Platz J., Mueller A., and Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 103 (2009) 22-29
20. Pulmonary Physiology Specialist Committee of the Japanese Respiratory Society. Report: standard values for spirometry and partial pressure of blood gas. [in Japanese]. J Jpn Respir Soc 39 (2001) 1-17
21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Available from (2007). http://www.goldcopd.org [accessed 21 August 2008]
22. Kesten S., Jara M., Wentworth C., and Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 130 (2006) 1695-1703
23. Kilfeather S.A., Ponitz H.H., Beck E., et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med 98 (2004) 387-397